1003: Disruptive Innovations in Clinical Neuroscience: Where Will We Find the Next Generation of Therapeutics?
Speaker: Thomas R. Insel, MD - Director, National Institute of Mental Health (NIMH), National Institutes of Health
Disclosures: Discussion of off-label uses will take place during this presentation. The speaker and the activity planners have no conflicts of interest to disclose.
Session Length: 90 minutes
Target Audience: RN, APRN
Upon completion of this presentation, the participant will be able to:
1. Describe the unmet medical needs of the consumers of mental health services.
2. Explain research findings related to recent findings in schizophrenia and autism.
3. Describe a model of moving practice to research.
Continuing Nursing Education
1.5 contact hours. * In order to receive contact hours, you must: Listen to the entire session, complete an evaluation, and earn a passing score on the post test before the expiration date. You will have 5 tries to correctly answer the questions on the post test. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. We cannot award credit unless all steps are completed.
The content of this CNE activity pertains to pharmacology. Because states' requirements may vary, contact your Board of Nursing for more information.
The American Psychiatric Nurses Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Friday, June 21, 2013 – 9:45am–11:15am
APNA 11th Annual Clinical Psychopharmacology Institute
Release Date: August 5, 2013
The contact hours for this session expire: September 1, 2016